A novel treatment strategy targeting cellular pathways with natural products to alleviate sarcopenia
Authors:
Open Access
- 4 August 2024
- journal article
- review article
- Published by Wiley in Phytotherapy Research
- Vol. 38 (11) , 5033-5051
Abstract
Sarcopenia is a condition marked by a significant reduction in muscle mass and strength, primarily due to the aging process, which critically impacts muscle protein dynamics, metabolic functions, and overall physical functionality. This condition leads to increased body fat and reduced daily activity, contributing to severe health issues and a lower quality of life among the elderly. Recognized in the ICD‐10‐CM only in 2016, sarcopenia lacks definitive treatment options despite its growing prevalence and substantial social and economic implications. Given the aging global population, addressing sarcopenia has become increasingly relevant and necessary. The primary causes include aging, cachexia, diabetes, and nutritional deficiencies, leading to imbalances in protein synthesis and degradation, mitochondrial dysfunction, and hormonal changes. Exercise remains the most effective intervention, but it is often impractical for individuals with limited mobility, and pharmacological options such as anabolic steroids and myostatin inhibitors are not FDA‐approved and are still under investigation. This review is crucial as it examines the potential of natural products as a novel treatment strategy for sarcopenia, targeting multiple mechanisms involved in its pathogenesis. By exploring natural products' multi‐targeted effects, this study aims to provide innovative and practical solutions for sarcopenia management. Therefore, this review indicates significant improvements in muscle mass and function with the use of specific natural compounds, suggesting promising alternatives for those unable to engage in regular physical activity.Keywords
Funding Information
- National Research Foundation of Korea (NRF‐2021R1F1A1A1063840)
This publication has 154 references indexed in Scilit:
- Corylifol A ameliorates muscle atrophy by inhibiting TAOK1/p38‐MAPK/FoxO3 pathway in cancer cachexiaJournal of Cachexia, Sarcopenia and Muscle, 2023
- Hierarchically Injectable Hydrogel Sequentially Delivers AntagomiR‐467a‐3p‐Loaded and AntagomiR‐874‐5p‐Loaded Satellite‐Cell‐Targeting Bioengineered Extracellular Vesicles Attenuating SarcopeniaAdvanced Healthcare Materials, 2023
- Ambra1 deficiency impairs mitophagy in skeletal muscleJournal of Cachexia, Sarcopenia and Muscle, 2022
- Targeting MuRF1 by small molecules in a HFpEF rat model improves myocardial diastolic function and skeletal muscle contractilityJournal of Cachexia, Sarcopenia and Muscle, 2022
- Daidzein alleviates cisplatin‐induced muscle atrophy by regulating Glut4/AMPK/FoxO pathwayPhytotherapy Research, 2021
- The role of SIRT1 in skeletal muscle function and repair of older miceJournal of Cachexia, Sarcopenia and Muscle, 2019
- 4E‐BP1 and 4E‐BP2 double knockout mice are protected from aging‐associated sarcopeniaJournal of Cachexia, Sarcopenia and Muscle, 2019
- Myricanol rescues dexamethasone‐induced muscle dysfunction via a sirtuin 1‐dependent mechanismJournal of Cachexia, Sarcopenia and Muscle, 2019
- Alterations in the in vitro and in vivo regulation of muscle regeneration in healthy ageing and the influence of sarcopeniaJournal of Cachexia, Sarcopenia and Muscle, 2017
- Welcome to the ICD‐10 code for sarcopeniaJournal of Cachexia, Sarcopenia and Muscle, 2016